Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma
Conditions
- Osteosarcoma
- Survival
- Chemotherapy Effect
- Toxicity, Drug
Interventions
- DRUG: MAPI chemotherapy
- DRUG: Apatinib Mesylate
- DRUG: Camrelizumab
Sponsor
Peking University People's Hospital
Collaborators